Healthcare provider profile · identity verified

Linn Larson, MD

Family Practice · MIDDLEBURY, VT · NPI 1609864768

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	185	42
Losartan Potassium	Losartan Potassium	166	46
Rosuvastatin Calcium	Rosuvastatin Calcium	120	40
Lisinopril	Lisinopril	118	34
Simvastatin	Simvastatin	114	28
Omeprazole	Omeprazole	113	42
Hydrochlorothiazide	Hydrochlorothiazide	110	30
Atorvastatin Calcium	Atorvastatin Calcium	98	28
Metoprolol Succinate	Metoprolol Succinate	81	24
Metformin Hcl	Metformin Hcl	65	19
Famotidine	Famotidine	61	21
Pantoprazole Sodium	Pantoprazole Sodium	56	18
Gabapentin	Gabapentin	55	20
Metoprolol Tartrate	Metoprolol Tartrate	52	15
Escitalopram Oxalate	Escitalopram Oxalate	50	20
Pravastatin Sodium	Pravastatin Sodium	49	16
Sertraline Hcl	Sertraline Hcl	48	15
Trazodone Hcl	Trazodone Hcl	46	17
Amlodipine Besylate	Amlodipine Besylate	44	16
Lorazepam	Lorazepam	44	15
Eliquis	Apixaban	43	11
Alendronate Sodium	Alendronate Sodium	35	suppressed
Estradiol	Estradiol	35	12
Atenolol	Atenolol	34	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	32	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	29	suppressed
Bupropion Xl	Bupropion Hcl	28	suppressed
Acyclovir	Acyclovir	27	suppressed
Prednisone	Prednisone	27	20
Albuterol Sulfate Hfa	Albuterol Sulfate	26	16
Ozempic	Semaglutide	26	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	26	suppressed
Celecoxib	Celecoxib	25	suppressed
Citalopram Hbr	Citalopram Hydrobromide	25	suppressed
Azithromycin	Azithromycin	24	20
Paroxetine Hcl	Paroxetine Hcl	23	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	22	suppressed
Breo Ellipta	Fluticasone/Vilanterol	20	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	20	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	19	16
Ezetimibe	Ezetimibe	19	suppressed
Januvia	Sitagliptin Phosphate	18	suppressed
Jardiance	Empagliflozin	18	suppressed
Sucralfate	Sucralfate	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	12
Furosemide	Furosemide	17	suppressed
Potassium Chloride	Potassium Chloride	17	suppressed
Risperidone	Risperidone	17	suppressed
Warfarin Sodium	Warfarin Sodium	17	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	16	suppressed
Duloxetine Hcl	Duloxetine Hcl	16	suppressed
Incruse Ellipta	Umeclidinium Bromide	16	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	15	suppressed
Allopurinol	Allopurinol	15	suppressed
Clonazepam	Clonazepam	15	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	14	suppressed
Metformin Hcl Er	Metformin Hcl	14	suppressed
Oxycodone Hcl	Oxycodone Hcl	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	13	suppressed
Meloxicam	Meloxicam	13	suppressed
Methadone Hcl	Methadone Hcl	13	suppressed
Spironolactone	Spironolactone	13	suppressed
Cephalexin	Cephalexin	12	12
Enalapril Maleate	Enalapril Maleate	12	suppressed
Irbesartan	Irbesartan	12	suppressed
Montelukast Sodium	Montelukast Sodium	12	suppressed
Morphine Sulfate	Morphine Sulfate	12	suppressed
Nystatin	Nystatin	12	suppressed
Tramadol Hcl	Tramadol Hcl	12	suppressed
Verapamil Er	Verapamil Hcl	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	11
Buspirone Hcl	Buspirone Hcl	11	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	11	suppressed
Fentanyl	Fentanyl	11	suppressed
Fluticasone Propionate	Fluticasone Propionate	11	suppressed
Myrbetriq	Mirabegron	11	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	11	11
Pregabalin	Pregabalin	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed
Trulicity	Dulaglutide	11	suppressed
Ventolin Hfa	Albuterol Sulfate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error